'Top drawer IP set.'
Legal 500 2010
'outstanding IP chambers'
Legal 500 2008
'8 New Square successfully parlays its renowned IP expertise into success in the IT sector.'
Chambers & Partners (Information Technology) 2009
'An incredibly good set for IP matters'.
Legal 500 2010
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
'excellence on IT matters'
Legal 500 (Information Technology) 2010
'A number of great IT and telecoms barristers.'
Legal 500 2010
'clerking team that exhibits 'perfect communication''
Legal 500 2008
Dr Reddy's Laboratories (UK) Limited v. Eli Lilly and Company Limited [2008] EWHC 2345 (Pat)
Case Summary | Judgment | 13 October 2008
The patent in suit was for a drug called olanzapine which is used in the treatment of schizophrenia. The Claimant sought to revoke the patent claiming that the patent was anticipated by and obvious in light of the Defendant's provisional patent as well as other prior art which it claimed disclosed the formula for olanzapine. The Judge held that although the general formula had been disclosed there had been no 'individualised disclosure' of the drug and it would not have been obvious to the skilled person to make olanzapine. Andrew Lykiardopoulos and James Whyte appeared as junior counsel for the Claimant in the trial heard in July 2008.